Novo A/S

Claim instruction:

Send us an email to claim@startus.cc from an official Novo A/S email account. The content must be:

StartUs buddies,

Please, allow me to claim rights over Novo A/S.

Best regards,
[your name]
Once sent the email click the Claim Startup button.
Our team will verify the origin account and will grant claim rights over the startup to the user if everything is ok.

https://www.startus.cc/company/novo-s

Tuborg Havnevej 19

2900 Hellerup

Denmark

Website

General information:

Novo A/S, a private limited liability company fully owned by the Novo Nordisk Foundation, is the holding company in the Novo Group, and responsible for managing the Foundation’s assets, which are currently valued at more than USD 40 billion.

Besides being the major shareholder in Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science and biotechnology, as well as manages a broad portfolio of financial assets.

As an international investor we work out of Copenhagen, San Francisco and London. Our teams of scientific and commercial experts actively support our portfolio of projects and companies, and manage our range of financial investments.

Company information:

Company type:

Investor

Industry:

Financial Services, Healthcare / Medical Services, Startup Services

Products and Services:

Novo Seeds

Product category:

Investor

To meet the challenges of a changing world, we need new and better healthcare solutions based on new inventions and technologies. Novo Seeds gives budding ideas the chance to develop into unique – and life-saving – products for the future. Our support is given through two types of programmes that target projects at different stages.
Capital is required for successful growth of a new project or company. However, it takes more than capital to transform pioneering ideas into viable solutions and healthy business platforms.

We use our commercial expertise to provide projects and companies with the managerial and strategic support that project owners need to steer through critical start-up phases. We also draw on our network from the regional and international biotech industry to provide the best expert advice.

By being actively involved in our investments, we ensure that each project has the optimal conditions for success – turning ideas and science into products that address significant healthcare needs.

Novo Ventures

Product category:

Investor

Novo Ventures is one of the most active life science venture capital investors in the world. So far, we have invested USD 800 million in more than 80 companies and successfully exited over 30 companies through trade sales and IPOs.

We proudly share our positive track record with the talented scientists and inspired entrepreneurs who convert our capital and commercial support into revolutionising products and technologies. Together, we’re improving the lives of thousands of people around the world.
We achieve results through long-term commitment and active collaboration. By working closely with our portfolio companies, we provide the commercial and scientific expertise to help them grow.

With activities in Copenhagen, San Francisco and London – and an international network of commercial and scientific specialists – we’re geared to reach the major hubs of life science. As a small team with short decision lines, we’re quick to respond to investment opportunities when they arise.

Our venture investment activities are structured as an open evergreen fund with Novo A/S as the sole investor. This allows us to take a long-term perspective when we make our investments. It also frees us from the frameworks that many traditional venture capital funds are bound by.

Large Investments

Product category:

Investor

At Novo, our investment span is broader than any other devoted life science investor. From nurturing pre-seed projects to deploying significant capital as cornerstone investors in fully fledged enterprises, we play an active role as a committed shareholder as these continue to profitably build and grow.
Our large scale, late-stage investment activities are targeted towards well-established life science companies that have positive cash flow, strongly positioned products and attractive prospects. Our goal is to create value through active support and long-term ownership.

These late-stage investments may amount to several billion DKK per company in exchange for influential equity ownership stakes in publicly listed as well as privately owned companies.